Polaris AI Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jason Kim
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 26yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 21yrs |
Recent management updates
Recent updates
Why EstechPharma Co., Ltd. (KOSDAQ:041910) Is A Top Dividend Stock
Apr 01
If You Had Bought EstechPharma's (KOSDAQ:041910) Shares Five Years Ago You Would Be Down 60%
Mar 06Declining Stock and Solid Fundamentals: Is The Market Wrong About EstechPharma Co., Ltd. (KOSDAQ:041910)?
Feb 07
We're Not So Sure You Should Rely on EstechPharma's (KOSDAQ:041910) Statutory Earnings
Jan 17Is EstechPharma Co., Ltd.'s (KOSDAQ:041910) 0.8% Dividend Worth Your Time?
Dec 22A Look At EstechPharma's (KOSDAQ:041910) Share Price Returns
Dec 01CEO
Jason Kim (64 yo)
26yrs
Tenure
Mr. Jae-Chul Kim, also known as Jason serves as the Chief Executive Officer and President of Polaris AI Pharma Corp. (formerly known as EstechPharma Co., Ltd.) Mr. Kim served at Central Research Center of...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Managing Director and Director | 21yrs | no data | no data | |
| Managing Director and Director | 21.1yrs | no data | no data | |
| Director | no data | no data | no data | |
| Director | no data | no data | no data | |
| Director | no data | no data | no data | |
| Director | 14.4yrs | no data | no data |
21.0yrs
Average Tenure
59yo
Average Age
Experienced Board: A041910's board of directors are seasoned and experienced ( 21 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 14:56 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Polaris AI Pharma Corp. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Al Eum Lee | iM Securities |
| Sung Hwan Choi | Kyobo Securities Co., Ltd |
| Kidal Bae | Shinhan Investment Corp. |